Podcast
Dr. Dobberfuhl discusses novel onabotulinumtoxinA treatment for refractory OAB
Author(s):
“This technique is feasible, it is very well tolerated, and there’s not much of a complication rate, so it appears to be very safe,” says Amy D. Dobberfuhl, MD, MS.
In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Amy D. Dobberfuhl, MD, MS, about the presentation, “Feasibility and efficacy of transvaginal onabotulinumtoxinA chemodenervation of the trigone for the third line treatment of refractory overactive bladder,” which was given at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction Winter Meeting. Dobberfuhl is a urologist at Stanford Hospitals and Clinics and an assistant professor of urology at the Stanford University School of Medicine in California.
Related Videos
Roger Dmochowski, MD, on real-world persistence with vibegron for OAB
Considerations for patient follow-up after onabotA administration
Administering onabotA: Improving patient comfort and easing anxiety
Experts discuss expanding use of vibegron for OAB
Ekene Enemchukwu, MD, on guideline-associated trends in OAB therapy use
Karyn S. Eilber, MD, on patient counseling for onabotA treatment for OAB
Optimizing onabotA for OAB: What are some common misconceptions?
Investigators characterize vibegron prescribing patterns for OAB
Expert outlines advantages of batteryless sacral neuromodulation device
Emmanuel Chartier-Kastler, MD, shares initial data on UroActive System in women with SUI
Related Content
